Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alteogen Inc. (196170.KQ)
Daejeon, KR
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.51% | -1.80% | +0.14% | -7.33% | -35.52% | -22.54% | +1.72% | +691.95% | +497.47% | +7,110.18% | +11,754.88% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+109.9% ★ Q1'26: -14.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+122.8% ★ Q1'26: -13.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+30.5% Q1'26: +70.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+45.8% ★ Q1'26: +54.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+74.1% ★ Q1'26: +107.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%0.0% ★ Q1'26: -0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.97× ★ Q1'26: 0.64× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 2 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.73B
est: 5.00B (-5.5%)
|
6.84B
est: 32.00B (-78.6%)
|
13.70B
est: 14.90B (-8.0%)
|
29.23B
est: 17.00B (+71.9%)
|
42.43B
est: 48.70B (-12.9%)
|
38.75B
est: 61.40B (-36.9%)
|
28.81B
est: 24.20B (+19.0%)
|
96.52B
est: 87.00B (+10.9%)
|
102.85B
est: 86.80B (+18.5%)
|
215.86B
est: 209.40B (+3.1%)
|
506.35B
384.39B – 570.13B
+141.8% YoY
|
849.72B
640.22B – 998.74B
+67.8% YoY
|
994.40B
751.37B – 1.15T
+17.0% YoY
|
| EBITDA |
337.87M
est: -403.45M (+183.7%)
|
-4.10B
est: -2.58B (-58.9%)
|
-5.46B
est: -1.20B (-353.7%)
|
-561.50M
est: -1.37B (+59.1%)
|
-15.03B
est: -3.93B (-282.4%)
|
-7.94B
est: -4.95B (-60.2%)
|
-6.89B
est: -1.95B (-252.8%)
|
440.04M
est: -7.02B (+106.3%)
|
40.14B
est: 7.53B (+432.9%)
|
104.29B
est: 18.17B (+474.0%)
|
43.94B
33.35B – 49.47B
+141.8% YoY
|
73.73B
55.55B – 86.66B
+67.8% YoY
|
86.28B
65.20B – 99.81B
+17.0% YoY
|
| EBIT |
1.05B
est: -657.41M (+260.2%)
|
-4.46B
est: -4.21B (-5.9%)
|
-6.01B
est: -1.96B (-206.7%)
|
-1.49B
est: -2.24B (+33.3%)
|
-16.89B
est: -6.40B (-163.8%)
|
-10.09B
est: -8.07B (-25.0%)
|
-9.54B
est: -3.18B (-200.0%)
|
-2.89B
est: -11.44B (+74.7%)
|
37.29B
est: 3.45B (+982.0%)
|
98.80B
est: 8.31B (+1,088.4%)
|
20.10B
15.26B – 22.64B
+141.8% YoY
|
33.74B
25.42B – 39.65B
+67.8% YoY
|
39.48B
29.83B – 45.67B
+17.0% YoY
|
| Net Income |
1.21B
|
-3.59B
est: 28.39B (-112.6%)
|
-6.87B
est: -6.87B (0.0%)
|
-704.51M
est: -4.97B (+85.8%)
|
-15.82B
est: 9.46B (-267.3%)
|
-6.27B
est: 10.14B (-161.9%)
|
-8.15B
est: -6.58B (-23.7%)
|
-3.37B
est: 15.26B (-122.1%)
|
62.25B
est: 22.49B (+176.8%)
|
141.67B
est: 77.05B (+83.9%)
|
289.77B
240.34B – 337.61B
+276.1% YoY
|
493.04B
413.29B – 574.70B
+70.1% YoY
|
708.95B
483.70B – 853.39B
+43.8% YoY
|
| SGA |
454.23M
est: 565.32M (-19.7%)
|
629.15M
est: 3.62B (-82.6%)
|
1.33B
est: 1.68B (-21.1%)
|
3.49B
est: 1.92B (+81.4%)
|
6.18B
est: 5.51B (+12.2%)
|
5.54B
est: 6.94B (-20.2%)
|
5.41B
est: 2.74B (+97.7%)
|
5.02B
est: 9.84B (-49.0%)
|
3.80B
est: 7.29B (-47.9%)
|
—
est: 17.58B (-100.0%)
|
42.51B
32.27B – 47.86B
+141.8% YoY
|
71.33B
53.75B – 83.84B
+67.8% YoY
|
83.48B
63.08B – 96.56B
+17.0% YoY
|
| EPS |
28.59
|
-82.74
est: 530.42 (-115.6%)
|
-151.13
est: -128.33 (-17.8%)
|
-14.62
est: -92.78 (+84.2%)
|
-209.53
est: 176.67 (-218.6%)
|
-103.31
est: 189.44 (-154.5%)
|
-158.85
est: -123.00 (-29.1%)
|
-65.27
est: 285.00 (-122.9%)
|
1,172.02
est: 420.33 (+178.8%)
|
2,652.97
est: 1,439.98 (+84.2%)
|
5,415.74
4,491.89 – 6,309.72
+276.1% YoY
|
9,214.67
7,724.15 – 10,740.76
+70.1% YoY
|
13,249.91
9,040.10 – 15,949.39
+43.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hang Yeon Kim | Chief Financial Officer & Executive Vice President | — | male |
| Kyuwan Kim | Senior Vice President & Head of New Drug Development | — | male |
| Sang Woo Kang | Senior Vice President of Management Support Group | — | male |
| Soon-Jae Park | Chief Executive Officer | — | — |
| Tae-Yon Chun | Executive Vice President & Corporate Alliance Officer | — | — |
| Vivek Shenoy | Chief Business Development Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 196170.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
